Emerging therapies and their delivery for treating age‐related macular degeneration. (12th May 2021)

• Record Type: Journal Article
• Authors: Thomas, Chloe N.; Sim, Dawn A.; Lee, Wen Hwa; Alfahad, Nada; Dick, Andrew D.; Denniston, Alastair K.; Hill, Lisa J.
• Other Names: Mauro Claudio guestEditor.; Naylor Amy guestEditor.; Lord Janet M. guestEditor.
• Is Part Of: British journal of pharmacology. Volume 179:Number 9(2022)
• Page Start: 1908
• Page End: 1937
• Publication Date: 2021-05-12
• Subjects: age‐related macular degeneration -- anti‐VEGF -- complement -- drug delivery -- immunotherapy -- ocular disease -- retina; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15459
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Age‐related macular degeneration (AMD) is the most common cause of blindness in the Western world and is characterised in its latter stages by retinal cell death and neovascularisation and earlier stages with the loss of parainflammatory homeostasis. Patients with neovascular AMD (nAMD) are treated with frequent intraocular injections of anti‐vascular endothelial growth factor (VEGF) therapies, which are not only unpopular with patients but carry risks of sight‐threatening complications. A minority of patients are unresponsive with no alternative treatment available, and some patients who respond initially eventually develop a tolerance to treatment. New therapeutics with improved delivery methods and sustainability of clinical effects are required, in particular for non‐neovascular AMD (90% of cases and no current approved treatments). There are age‐related and disease‐related changes that occur which can affect ocular drug delivery. Here, we review the latest emerging therapies for AMD, their delivery routes and implications for translating to clinical practice. LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc Abstract :